Galapagos NV GLPG
Dividend Summary
There have not been any declared dividends recently.
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | – | – |
| Type | – | – |
| Per share | – | – |
| Declaration date | – | – |
| Ex-div date | – | – |
| Pay date | – | – |
Enter the number of Galapagos NV shares you hold and we'll calculate your dividend payments:
Sign up for Galapagos NV and we'll email you the dividend information when they declare.
Add Galapagos NV to receive free notifications when they declare their dividends.
Your account is set up to receive Galapagos NV notifications.
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| There are no Galapagos NV dividends. | ||||||||
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0¢ | — |
| 2007 | 0.0¢ | 0% |
| 2008 | 0.0¢ | 0% |
| 2009 | 0.0¢ | 0% |
| 2010 | 0.0¢ | 0% |
| 2011 | 0.0¢ | 0% |
| 2012 | 0.0¢ | 0% |
| 2013 | 0.0¢ | 0% |
| 2014 | 0.0¢ | 0% |
| 2015 | 0.0¢ | 0% |
| 2016 | 0.0¢ | 0% |
| 2017 | 0.0¢ | 0% |
| 2018 | 0.0¢ | 0% |
| 2019 | 0.0¢ | 0% |
| 2020 | 0.0¢ | 0% |
| 2021 | 0.0¢ | 0% |
| 2022 | 0.0¢ | 0% |
| 2023 | 0.0¢ | 0% |
| 2024 | Sign Up Required | |
Galapagos NV Optimized Dividend Chart
- Dividend Yield Today
- 0.0%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 0.0% on 24 November 2023
- 52 Week Low
- 0.0% on 24 November 2023
- Next Ex-Div-Date Countdown
- Sign Up Required
About Galapagos NV
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives.
Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gielad in Phase 3 in rheumatoid arthritis, Crohn's disease and ulcerative colitis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- Netherlands
- Share Price
- €23.96 (yesterday's closing price)
- Shares in Issue
- 66 million
- Market Cap
- €1.6bn
- 0
- Market Indices
- AEX 25, BEL 20, STOXX600
- Home Page URL
- http://www.glpg.com/
- Financial Calendar URL
- Sign Up Required
